北京招聘

?       Acts as the point of contact with patient organizations, defines the strategy & objectives of collaboration with patient organizations together with marketing, medical and MA team, and integrating patient advocates as part of CANbridge rare disease strategies

?       Develops and maintains strong and continuous relationships with patient groups, determines their interests and develops appropriate communication strategies and initiatives to reach and engage these groups

?       Coordinates and organizes rare disease advocacy events, preparing topics for key congresses, internal engagements, media opportunities to shape and support the environment in driving rare disease awareness/education and patient access to diagnosis, treatment and appropriate care, etc.

?       Lead the development of patient-facing educational materials across the Rare Diseases portfolio

?       Providing strong project management/leadership on key communications activities and initiatives, ensuring they are completed on time with a high level of quality, in accordance with Compliance, Medical, Legal and Regulatory requirements

?       Manage the advocacy budget, identifying and supervising management of external strategic partners, budget sponsorships and charitable donations (such as PAP)

 

Qualifications

·         University degree preferably in Business Administration, Political Science, International Relations, and Communications

·         5-8 years’work experience; Healthcare sector, Market Access or Patient Interaction experience (preferred)

·         Knowledge and experience of the patient advocacy environment

·         Strong organizational and communication skills

·         Rare disease experience is a plus

• Advanced level of English both oral and written

北海康成（北京）医药科技有限公司正式成立于2012年6月，总部设立在中关村望京科技创业园区内。
北海康成致力于解决满足“三个需求”，即满足中国患者对高效药物的需求、中国药企关键技术、产品更新换代的需求、发达国家中小生物制药企业进入中国市场的需求。
北海康成通过技术转让、吸收和再创新对接世界最大的生命高科技医药产品线与全球增长最快、潜力最大的应用市场。公司引进、研发、上市的重点是中国和亚洲市场所急需的特效药物。北海康成已经与欧美创新型生物制药公司、研究机构开展多个抗癌药物领域的技术合作。公司注重临床后期新药开发，有针对性地获取尖端的或国内新药研发所急需的制剂和生产工艺方面的成果，通过再创新和技术转化研发上市拥有自主知识产权的医药产品。